Mental Health + Weight Loss

Many factors contribute to our overall wellbeing regarding our Mental Health. We recognize that mental health illnesses effect our relationship with food. We want to treat the whole person by using a variety of solutions when it comes to mental health and weight loss.

Common Eating Disorders:

Common eating disorders include anorexia nervosa, bulimia nervosa, binge-eating disorder, and avoidant restrictive food intake disorder. Each of these disorders is associated with different but sometimes overlapping symptoms.

Although eating disorders all have food and weight issues in common, most experts now believe that eating disorders are caused by people attempting to cope with overwhelming feelings and painful emotions by controlling food.


Why Do We Offer A Weight Loss Solution?

In addition to physical health benefits, losing weight can have a big impact on mental health and wellbeing. Some of the benefits are:

  • Improved mental health

  • Greater self esteem

  • Being less self-conscious

  • Feeling more assertive at work

  • Feeling happier

  • Feeling more sociable and have more fun

  • Having a sense of achievement

  • Greater self confidence

What Weight Loss Service Do We Offer?

Semaglutide (Rx)

Brand and Other Names: Ozempic, Rybelsus, WeGovy

Dosage Forms & Strengths

injection, prefilled, single-dose pen (Ozempic)

  • 2mg/1.5mL (1.34mg/mL); delivers doses of 0.25mg or 0.5mg per injection

  • 4mg/3mL (1.34mg/mL); delivers 1mg per injection

  • 8mg/3mL (2.68 mg/mL); delivers 2mg per injection

injection, prefilled, single-dose pen (Wegovy)

  • 0.25mg/0.5mL

  • 0.5mg/0.5mL

  • 1mg/0.5mL

  • 1.7mg/0.75mL

  • 2.4mg/0.75mL

oral tablet (Rybelsus)

  • 3mg

  • 7mg

  • 14mg

Weight Management

Wegovy only

Indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, dyslipidemia)

Initiate with low dose and gradually escalate to maintenance dose of 2.4 mg/week SC to minimize GI adverse reactions

If unable to tolerate a dose during escalation, consider delaying dose escalation for 4 weeks

If unable to tolerate maintenance dose of 2.4 mg once-weekly, may temporarily decreased to 1.7 mg once weekly, for a maximum of 4 weeks; after 4 weeks, increase back to maintenance 2.4 mg once-weekly; discontinue if not tolerated after second attempt

In patients with type 2 diabetes, monitor blood glucose before initiating and during treatment

Once weekly SC dose escalation schedule

  • Weeks 1-4: 0.25 mg

  • Weeks 5-8: 0.5 mg

  • Weeks 9-12: 1 mg

  • Week 13-16: 1.7 mg

  • Week 17 and onward: 2.4 mg (maintenance)

Dosage Modifications

Renal or hepatic impairment

  • No dosage adjustment required

Upper GI tract disease

  • PO: No dosage adjustment required

Dosing Considerations

Limitations of use

  • Not studied in patients with a history of pancreatitis

  • Ozempic, Rybelsus (T2DM)

    • SC semaglutide is not a substitute for insulin

    • Not indicated for type 1 diabetes mellitus or for treatment of diabetic ketoacidosis, as it would not be effective in these settings

  • Wegovy (weight management)

    • Contains semaglutide and should not be coadministered with other semaglutide-containing products or with any other GLP-1 receptor agonist

    • Safety and effectiveness in combination with other products intended for weight loss, including prescription drugs, OTC drugs, and herbal preparations, have not been established.